AI-Driven Genomics
for Pharma

We Deliver Profound Insight into the
Genetic Drivers of Disease

DISCOVER NEW EVIDENCE
Gain research-driven understanding with Genomic Landscapes for Neurodegenerative Diseases

Pharma companies need comprehensive genomic information to drive successful precision medicine programs, but decisions are often made using only a fraction of the data available…about 10%.
Genomenon delivers 100% of the data.

5X More Variants in Weeks

Genomenon identified all of the genomic drivers in TARDBP associated with ALS in just two weeks…a yield of 435% more than the number of disease-causing variants found in ClinVar


Comprehensive

Don’t miss anything – get insight into every genomic biomarker published in the medical literature

Evidence-Based

Every scientific assertion is supported by empirical evidence from the medical literature

5X More Variants in Weeks

TALK TO US ABOUT YOUR GENOMIC DATA NEEDS

De-Risk Your Precision Medicine Program


<p style="color:#003478;"><strong>FIND  & VALIDATE THE RIGHT TARGETS FASTER</strong></p>

FIND & VALIDATE THE RIGHT TARGETS FASTER

Identify all genetic drivers of a disease or pathway and pinpoint which variants are known to be pathogenic

<p style="color:#003478;"><strong>IDENTIFY THE RIGHT PATIENTS FOR YOUR TRIAL</strong></p>

IDENTIFY THE RIGHT PATIENTS FOR YOUR TRIAL

Expand patient population and identify therapies known to be efficacious with comprehensive biomarker information

<p style="color:#003478;"><strong>DE-RISK & PRIORITIZE INVESTMENT DECISIONS</strong></p>

DE-RISK & PRIORITIZE INVESTMENT DECISIONS

Accelerate the decision-making process, validate promising research, and eliminate false targets

Learn how a leading rare disease pharma company leveraged genomics to target their clinical trials.

Genomenon Genomic Landscapes provide the complete picture of a disease or pathway with a unique 2-pronged approach

Robot-Human-Cyborg 2020-robot

AI-Driven

Genomenon’s Computational Intelligence organizes and indexes all medical evidence and makes it easily searchable

Robot-Human-Cyborg 2020-human

Expertly Curated

Genomenon’s Experts assess the variants for clinical effect, score for pathogenicity, and review to ensure data quality

ALS GENOMIC LANDSCAPE NOW AVAILABLE!

Genomenon’s comprehensive and organized collection of genomic evidence significantly accelerated our work in several key steps along our development process.


<h5>Vice President, Translational Research & Development,  Rare Disease Pharmaceutical Company<h5>
Vice President, Translational Research & Development, Rare Disease Pharmaceutical Company

Genomenon’s methodology improved the efficiency and completeness of our literature review process.


<h5>Vice President, Translational Research & Development,  Rare Disease Pharmaceutical Company<h5>
Vice President, Translational Research & Development, Rare Disease Pharmaceutical Company

EXPLORE OUR FULL CAPABILITIES FOR PHARMA